Adolescent BCG revaccination induces a phenotypic shift in CD4+ T cell responses to Mycobacterium tuberculosis
One Dintwe, Lamar Ballweber-Fleming, Valentin Voillet, John McNevin, Aaron Seese, Anneta Naidoo, Saleha Omarjee, Linda‐Gail Bekker, et al. (14 authors)
Nature Communications · 2024-06
Abstract
Abstract A recent clinical trial demonstrated that Bacille Calmette-Guérin (BCG) revaccination of adolescents reduced the risk of sustained infection with Mycobacterium tuberculosis ( M.tb ). In a companion phase 1b trial, HVTN 602/Aeras A-042, we characterize in-depth the cellular responses to BCG revaccination or to a H4:IC31 vaccine boost to identify T cell subsets that could be responsible for the protection observed. High-dimensional clustering analysis of cells profiled using a 26-color flow cytometric panel show marked increases in five effector memory CD4 + T cell subpopulations (T EM ) after BCG revaccination, two of which are highly polyfunctional. CITE-Seq single-cell analysis shows that the activated subsets include an abundant cluster of Th1 cells with migratory potential. Additionally, a small cluster of Th17 T EM cells induced by BCG revaccination expresses high levels of CD103; these may represent recirculating tissue-resident memory cells that could provide pulmonary immune protection. Together, these results identify unique populations of CD4 + T cells with potential to be immune correlates of protection conferred by BCG revaccination.
MeSH terms
- Mycobacterium tuberculosis
- Immune system
- Immunology
- Tuberculosis
- Phenotype
- Effector
- Vaccination
- BCG vaccine
- T cell
- Biology
- Cytotoxic T cell
- Virology
- Medicine